Pierre Blanchard, MD
@PBlanchardMD
Full Prof Radiation Oncology @gustaveroussy @UnivParisSaclay. EiC https://t.co/ZZv4fFrcCi. Director @SciencesCancer. Adjunct Assoc Prof @MDAndersonNews.
ID:3265085554
17-05-2015 07:52:33
3,9K Tweets
4,8K Followers
298 Following
Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by Pierre Blanchard, MD Gustave Roussy. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/4aVAN1S Advanced Prostate Cancer Consensus Conference
Great to have the opportunity to discuss with my friend Thomas Zilli the current status and future of prostate/mets radiotherapy in #prostatecancer at #APCCC24 .
Thanks Uromigos Tom Powles Brian Rini, MD for the invitation!
• Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?- Pierre Blanchard, MD
Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala
And it’s a wrap! It’s been a wonderful and exciting conference. Thanks silke gillessen aurelius omlin and Advanced Prostate Cancer Consensus Conference !
Let’s meet all in 2026 for #APCCC26
And next year for APCCC Diagnostics led by Ken Herrmann and prof. Stefano Fanti
#APCCC24
Brilliant lecture by Michael Hofman on differences between PSMA tracers for diagnostics and therapy in #prostatecancer
1. PSMA11, DCFPyL or PSMA7 likely interchangeable
2. For therapy PSMA617 and I&T: likely radio equivalent
#APCCC24
Prof Louise Emmett’s take on special situations for PSMA radioligand therapy for advanced #prostatecancer :
1. Bone marrow dysfunction: if RLT, then full dose (usually diffuse disease) & monitor closely
2. Kidney failure: renal toxicity not an early issue
#APCCC24
#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Pierre Blanchard, MD ‘s excellent talk on serum testosterone suppression after limited ADT and testosterone recovery 👉implications on QOL, & testosterone replacement Rx👇OncoAlert Oncology Brothers UroToday.com PCF Science Courtney Bugler
Pierre Blanchard, MD Piet Ost Very cogent points made that N0M0 on next gen imaging is a completely different population than that of STAMPEDE. This is why #APCCC24 is so important: imaging and treatment practices have evolved, leading to huge gaps in the evidence that we must identify and then fill.
Excellent talk by Daniel E Spratt at #APCCC24 on genomic and MMAI classifiers in M0 #prostatecancer .
Issues remain about access, dichotomization and added value compared to currently used risk markers (% positive cores, length of Pattern 4, MRI T stage, PSA density…)